Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Imetelstat Study Blip Beats Geron’s Shares Down

Executive Summary

Shares in Geron dropped by nearly 20% to $2.30 on NASDAQ on Sept. 12 following interim clinical data for its lead product, the anticancer imetelstat, from trials conducted by its partner Janssen.

You may also be interested in...

Geron Sees Blockbuster Opportunity For Imetelstat, Eyeing Broader Market Than Reblozyl’s

The company reported positive results from its study in lower-risk myelodysplastic syndrome, where it forecasts a market potentially exceeding 30,000 in US and major European markets and generating up to $1.2bn in sales.

Imetelstat Trial Update Lift Geron, Despite Indecision By Partner J&J

News of continuation of myelofibrosis and myelodysplastic syndromes studies well-received in market, despite global partner J&J's apparent reluctance to commit to imetelstat for the long haul.

Misery In Myelofibrosis: Pacritinib Setback A Boost For Jakafi

With the commercial opportunity in the myelofibrosis market expected to double to over $1bn in the next five years, competition to Incyte/Novartis's Jakafi seems further away than ever as CTI BioPharma pulls the European regulatory filing for pacritinib.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts